Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025MedicineOpen Access

The role of cerebrospinal fluid metabolites in the pathogenesis of lung adenocarcinoma: An observational study using Mendelian randomization

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXingcheng ZhuYFYuanzhi FuLZLin Zhu

Discussion

Loading...

Member takes

Overview

Observational analysis reveals how cerebrospinal fluid metabolites may influence lung adenocarcinoma risk, suggesting complex metabolic interactions.

Key Points

  • Forward Mendelian randomization identified 7 cerebrospinal fluid metabolites associated with lung adenocarcinoma risk, highlighting their potential roles.
  • The study involved analyzing data from 11,273 lung cancer patients and 55,483 controls, focusing on genetic variants linked to each metabolite.
  • Two-sample Mendelian randomization was employed alongside sensitivity analyses to assess the robustness of the findings regarding causality.
  • The implications of these findings suggest that cerebrospinal fluid metabolites might significantly contribute to lung adenocarcinoma development.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/68dd91d5fe798ba2fc4990d8https://doi.org/10.1097/md.0000000000044710
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inflammatory factors and risk of lung adenocarcinoma: a Mendelian randomization study mediated by blood metabolites2024 · 7 citations
  2. 2Plasma metabolomics reveals risk factors for lung adenocarcinoma2024 · 5 citations
  3. 3The causal association between serum metabolites and lung cancer based on multivariate Mendelian randomization2024 · 3 citations
  4. 4The Role of Metabolites in CSF on NAFLD Development: A Mendelian Randomisation Analysis2025
  5. 5Multiomic Mendelian randomization analysis of metabolic gene methylation expression and protein levels in lung adenocarcinoma2025